ALLIANCEBERNSTEIN L.P. - ACLARIS THERAPEUTICS INC ownership

ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 87 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of ACLARIS THERAPEUTICS INC
ValueSharesWeighting
Q1 2024$74,896
+18.1%
60,4000.0%0.00%
Q4 2023$63,420
-84.7%
60,4000.0%0.00%
Q3 2023$413,740
-33.9%
60,4000.0%0.00%
Q2 2023$626,348
+28.2%
60,4000.0%0.00%
Q1 2023$488,636
-48.6%
60,4000.0%0.00%
Q4 2022$951,300
+31.0%
60,400
+31.0%
0.00%
Q3 2022$726,000
+12.7%
46,1000.0%0.00%
Q2 2022$644,000
-10.7%
46,100
+10.3%
0.00%
Q1 2022$721,000
+52.1%
41,800
+28.2%
0.00%
Q4 2021$474,000
-5.2%
32,600
+17.3%
0.00%
Q3 2021$500,000
+2.5%
27,8000.0%0.00%
Q2 2021$488,000
+756.1%
27,800
-49.6%
0.00%
Q1 2020$57,000
-45.2%
55,2000.0%0.00%
Q4 2019$104,000
+73.3%
55,2000.0%0.00%
Q3 2019$60,000
-50.4%
55,2000.0%0.00%
Q2 2019$121,000
-57.5%
55,200
+16.2%
0.00%
Q1 2019$285,000
-2.4%
47,500
+20.3%
0.00%
Q4 2018$292,000
-35.0%
39,500
+27.8%
0.00%
Q3 2018$449,000
-21.9%
30,900
+7.3%
0.00%
Q2 2018$575,000
+39.2%
28,800
+22.0%
0.00%
Q1 2018$413,000
-14.1%
23,600
+21.0%
0.00%
Q4 2017$481,000
-4.4%
19,5000.0%0.00%
Q3 2017$503,000
-4.9%
19,5000.0%0.00%
Q2 2017$529,000
+91.0%
19,500
+109.7%
0.00%
Q1 2017$277,000
+35.8%
9,300
+24.0%
0.00%
Q4 2016$204,0007,5000.00%
Other shareholders
ACLARIS THERAPEUTICS INC shareholders Q3 2018
NameSharesValueWeighting ↓
BML Capital Management, LLC 12,988,134$14,286,94710.20%
Stonepine Capital Management, LLC 1,927,446$2,120,1911.95%
Aldebaran Capital, LLC 858,152$943,9670.88%
Acuitas Investments, LLC 464,120$510,5320.27%
Trium Capital LLP 1,892,050$2,0810.26%
Aisling Capital Management LP 434,455$477,9010.21%
Samsara BioCapital, LLC 696,171$765,7880.16%
Deuterium Capital Management, LLC 72,091$79,3000.13%
Bain Capital Life Sciences Investors, LLC 1,000,000$1,100,0000.12%
Rock Springs Capital Management LP 2,753,495$3,028,8450.09%
View complete list of ACLARIS THERAPEUTICS INC shareholders